



Elizabeth Ponder

Executive Director, Sarafan ChEM-H

Bio

BIO

Dr. Elizabeth Ponder joined Stanford ChEM-H in 2014 and is currently the Executive Director of Sarafan ChEM-H and the Stanford Innovative Medicines Accelerator (IMA). Dr. Ponder completed her Ph.D. and postdoctoral training at Stanford University in the laboratory of Dr. Matthew Bogyo. Her past work has included promoting public-private partnerships in the non-profit sector, managing multidisciplinary research in the higher education sector, and business development consulting in the for-profit biotech sector. Dr. Ponder joined ChEM-H from the University of California, Berkeley where she served as the Executive Director of the Henry Wheeler Center for Emerging & Neglected Diseases (CEND).

EDUCATION AND CERTIFICATIONS

- Postdoctoral Fellow, Stanford University , Pathology (2010)
- PhD, Stanford University , Microbiology & Immunology (2009)
- BS, Lafayette College , Biochemistry (2004)

LINKS

- Sarafan ChEM-H: <https://chemh.stanford.edu/>

Publications

PUBLICATIONS

- **Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Holubar, M., Subramanian, A., Purington, N., Hedlin, H., Bunning, B., Walter, K. S., Bonilla, H., Boumis, A., Chen, M., Clinton, K., Dewhurst, L., Epstein, C., Jagannathan, et al
2022
- **Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.** *PLoS neglected tropical diseases*
Ekins, S., Lage de Siqueira-Neto, J., McCall, L., Sarker, M., Yadav, M., Ponder, E. L., Kallel, E. A., Kellar, D., Chen, S., Arkin, M., Bunin, B. A., McKerrow, J. H., Talcott, et al
2015; 9 (6)
- **Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor with Parasite-Specific Toxicity** *CHEMISTRY & BIOLOGY*
Li, H., Ponder, E. L., Verdoes, M., Asbjornsdottir, K. H., Deu, E., Edgington, L. E., Lee, J. T., Kirk, C. J., Demo, S. D., Williamson, K. C., Bogyo, M.
2012; 19 (12): 1535-1545
- **Development of Small Molecule Inhibitors and Probes of Human SUMO Deconjugating Proteases** *CHEMISTRY & BIOLOGY*
Albrow, V. E., Ponder, E. L., Fasci, D., Bekes, M., Deu, E., Salvesen, G. S., Bogyo, M.
2011; 18 (6): 722-732

- **Functional Characterization of a SUMO Deconjugating Protease of *Plasmodium falciparum* Using Newly Identified Small Molecule Inhibitors** *CHEMISTRY & BIOLOGY*
Ponder, E. L., Albrow, V. E., Leader, B. A., Bekes, M., Mikolajczyk, J., Fonovic, U. P., Shen, A., Drag, M., Xiao, J., Deu, E., Campbell, A. J., Powers, J. C., Salvesen, et al
2011; 18 (6): 711-721
- **Simplified, Enhanced Protein Purification Using an Inducible, Autoprocessing Enzyme Tag** *PLOS ONE*
Shen, A., Lupardus, P. J., Morell, M., Ponder, E. L., Sadaghiani, A. M., Garcia, K. C., Bogyo, M.
2009; 4 (12)
- **Identification of proteases that regulate erythrocyte rupture by the malaria parasite *Plasmodium falciparum*** *NATURE CHEMICAL BIOLOGY*
Arastu-Kapur, S., Ponder, E. L., Fonovic, U. P., Yeoh, S., Yuan, F., Fonovic, M., Grainger, M., Phillips, C. I., Powers, J. C., Bogyo, M.
2008; 4 (3): 203-213
- **Ubiquitin-like modifiers and their deconjugating enzymes in medically important parasitic protozoa** *EUKARYOTIC CELL*
Ponder, E. L., Bogyo, M.
2007; 6 (11): 1943-1952